⌕
Praxis Precision Medicines · PRAX · Nasdaq
Tenet 45 · Mixed
Compare
$307.78−6.20%Market openTenet 45 · Mixed
$307.78−20.35 (−6.20%)
Market open · 15-min delayed · as of 1:58 PM ET· Nasdaq · USD

Praxis Precision Medicines (PRAX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is PRAX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 16, 2026 · 11:02 ET
Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Transcript

Praxis Precision Medicines, Inc. ( PRAX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Joon Lee - UBS Inves…

PRAX −6.2% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 04:21 ETEARNINGS EXPECTED BY FEB 16
Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)

I maintain a Strong Buy on Praxis Precision Medicines, with a $601 fair value, 85% above the November 12 close. The valuation falls from $664 primarily after correcting the share count for pre-funded warrants and options…

PRAX −6.2% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day

Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027…

PRAX −6.2% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 14:59 ET
Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly - CFO & Treasurer Conf…

PRAX −6.2% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results

FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of relutrigine…

PRAX −6.2% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that o…

PRAX −6.2% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it wil…

PRAX −6.2% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that o…

PRAX −6.2% todayRead at source ↗
● Defense WorldOct 2, 2026 · 06:15 ETEARNINGS EXPECTED BY FEB 16
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)

Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companie…

PRAX −6.2% todayRead at source ↗
● Defense WorldSep 21, 2026 · 02:29 ET
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, MarketBeat reports. Two analysts have…

PRAX −6.2% todayRead at source ↗
● Seeking AlphaSep 12, 2026 · 10:38 ET
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)

Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, under…

PRAX −6.2% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that …

PRAX −6.2% todayRead at source ↗
● Defense WorldAug 27, 2026 · 02:30 ET
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Buy” from Brokerages

Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports.…

PRAX −6.2% todayRead at source ↗
● Defense WorldAug 18, 2026 · 03:45 ET
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High – What’s Next?

Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at $376.38, with a volume of 58…

PRAX −6.2% todayRead at source ↗
● Defense WorldAug 16, 2026 · 03:46 ETEARNINGS EXPECTED BY FEB 16
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The ins…

PRAX −6.2% todayRead at source ↗

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA15−4.3%
UBS4−1.3%
INTC3−7.4%

Article counts from the last market-wide feed page, across every symbol we track and not just PRAX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.